GGrantIndex
← Leaderboards

Morton Cowan

University Of California San Francisco

$11,226,923
Attributed
$11,256,923
Total exposure
10
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.9M · FY200518
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18

Funding mix

By agency

NIH$22,463,267 · 11

By mechanism

U54$20,300,514 · 5
R01$1,987,950 · 2
R13$134,000 · 1
M01$36,639 · 2
P41$4,164 · 1

Top collaborators

Most similar at University Of California San Francisco

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research

Research focus

Clinical ResearchImmuneSevere Combined ImmunodeficiencyBiological MarkersNorth AmericaLifeWiskott-Aldrich SyndromeClinical TrialsChildChronic Granulomatous DiseaseProspectiveInterestRare DiseasesEducational WorkshopResearch PersonnelBaseHematopoietic Cell TransplantationProtocols DocumentationMeetingsAsiaCaringEuropeBone Marrow TransplantationFaculty

Grant awards (43)

PIDTC Administrative Unit$1,281,048
U54 · FY2018 · AI · contact PI
PIDTC Administrative Unit$1,236,689
U54 · FY2017 · AI · contact PI
ConProject-005$74,342
U54 · FY2017 · AI · contact PI
Primary Immune Deficiency Treatment Consortium Annual Scientific Meeting$18,000
R13 · FY2017 · AI · contact PI
Primary Immune Deficiency Treatment Consortium$1,528,517
U54 · FY2016 · AI · contact PI
PIDTC Administrative Unit$1,281,662
U54 · FY2016 · AI · contact PI
Primary Immune Deficiency Treatment Consortium Annual Scientific Meeting$14,000
R13 · FY2016 · AI · contact PI
Primary Immune Deficiency Treatment Consortium$1,543,499
U54 · FY2015 · AI · contact PI
PIDTC Administrative Unit$1,296,622
U54 · FY2015 · AI · contact PI
Primary Immune Deficiency Treatment Consortium Annual Scientific Meeting$18,000
R13 · FY2015 · AI · contact PI
Primary Immune Deficiency Treatment Consortium$1,249,464
U54 · FY2014 · AI · contact PI
PIDTC Administrative Unit$856,392
U54 · FY2014 · AI · contact PI
Primary Immune Deficiency Treatment Consortium Annual Scientific Meeting$24,000
R13 · FY2014 · AI · contact PI
Primary Immune Deficiency Treatment Consortium$1,455,444
U54 · FY2013 · AI · contact PI
Primary Immune Deficiency Treatment Consortium Administrative Unit$778,708
U54 · FY2013 · AI · contact PI
Clinical Sites Consortiums$373,350
U54 · FY2013 · AI · contact PI
Primary Immune Deficiency Treatment Consortium Annual Scientific Meeting$20,000
R13 · FY2013 · AI · contact PI
Primary Immune Deficiency Treatment Consortium$1,530,119
U54 · FY2012 · AI · contact PI
Primary Immune Deficiency Treatment Consortium Administrative Unit$781,599
U54 · FY2012 · AI · contact PI
Clinical Sites Consortiums$391,244
U54 · FY2012 · AI · contact PI
Primary Immune Deficiency Treatment Consortium Annual Scientific Meeting$20,000
R13 · FY2012 · AI · contact PI
Primary Immune Deficiency Treatment Consortium$1,416,193
U54 · FY2011 · AI · contact PI
Primary Immune Deficiency Treatment Consortium Administrative Unit$433,867
U54 · FY2011 · AI · contact PI
Clinical Sites Consortiums$308,647
U54 · FY2011 · AI · contact PI
Primary Immune Deficiency Treatment Consortium Annual Scientific Meeting$20,000
R13 · FY2011 · AI · contact PI
Primary Immune Deficiency Treatment Consortium$1,233,108
U54 · FY2010 · AI · contact PI
Primary Immune Deficiency Treatment Consortium$1,250,000
U54 · FY2009 · AI · contact PI
Tolerance post in utero transplantation$265,125
R01 · FY2005 · HL
ID OF DNA PK DEPENDENT KINASE SITES OF PHOSPHORYLATION ON ARTEMIS PROTEIN$4,134
P41 · FY2005 · RR
BONE MARROW STEM CELL TRANSPLANTATION FOR CHILDREN$3,303
M01 · FY2005 · RR
Tolerance post in utero transplantation$265,125
R01 · FY2004 · HL
Bone marrow stem cell transplantation for children$7,537
M01 · FY2004 · RR
ID OF DNA PK DEPENDENT KINASE SITES OF PHOSPHORYLATION ON ARTEMIS PROTEIN$30
P41 · FY2004 · RR
Tolerance post in utero transplantation$264,688
R01 · FY2003 · HL
Tolerance post in utero transplantation$262,719
R01 · FY2002 · HL
BUSULFAN PHARMACOKINETICS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION$0
M01 · FY2002 · RR
GENE LINKAGE STUDY OF IMMUNODEFICIENCY IN NAVAJO INDIANS$484,647
R01 · FY2001 · AI
BUSULFAN PHARMACOKINETICS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION$0
M01 · FY2001 · RR
GENE LINKAGE STUDY OF IMMUNODEFICIENCY IN NAVAJO INDIANS$254,616
R01 · FY2000 · AI
TOLERANCE POST IN UTERO TRANSPLANTATION$191,030
R01 · FY2000 · HL
BUSULFAN PHARMACOKINETICS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION$25,799
M01 · FY2000 · RR
BUSULFAN PHARMACOKINETICS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION$0
M01 · FY2000 · RR
BUSULFAN PHARMACOKINETICS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION$0
M01 · FY2000 · RR